Literature DB >> 23197891

Effectiveness of Saccharomyces boulardii in a rat model of colitis.

Mujde Soyturk1, Saba Mukaddes Saygili, Huseyin Baskin, Ozgul Sagol, Osman Yilmaz, Fatih Saygili, Hale Akpinar.   

Abstract

AIM: To investigate the effects of Saccharomyces boulardii (S. boulardii) in an experimental rat model of trinitrobenzene sulfonic acid (TNBS)-induced colitis.
METHODS: Thirty-two Wistar albino female rats were categorized into five groups. On the first day of the study, 50 mg TNBS was administered via a rectal catheter in order to induce colitis in all rats, except those in the control group. For 14 d, the rats were fed a standard diet, without the administration of any additional supplements to either the control or TNBS groups, in addition to 1 mg/kg per day S. boulardii to the S. boulardii group, 1 mg/kg per day methyl prednisolone (MP) to the MP group. The animals in the S. boulardii + MP group were coadministered these doses of S. boulardii and MP. During the study, weight loss, stool consistency, and the presence of obvious blood in the stool were evaluated, and the disease activity index (DAI) for colitis was recorded. The intestines were examined and colitis was macro- and microscopically scored. The serum and tissue levels of tumor necrosis factor-α (TNF-α) and nitric oxide (NO) were determined, and fungemia was evaluated in the blood samples.
RESULTS: The mean DAI scores for the MP and S. boulardii + MP groups was significantly lower than the TNBS group (3.69 ± 0.61 vs 4.46 ± 0.34, P = 0.018 and 3.77 ± 0.73 vs 4.46 ± 0.34, P = 0.025, respectively). While no significant differences between the TNBS and the S. boulardii or MP groups could be determined in terms of serum NO levels, the level of serum NO in the S. boulardii + MP group was significantly higher than in the TNBS and S. boulardii groups (8.12 ± 4.25 μmol/L vs 3.18 ± 1.19 μmol/L, P = 0.013; 8.12 ± 4.25 μmol/L vs 3.47 ± 1.66 μmol/L, P = 0.012, respectively). The tissue NO levels in the S. boulardii, MP and S. boulardii + MP groups were significantly lower than the TNBS group (16.62 ± 2.27 μmol/L vs 29.72 ± 6.10 μmol/L, P = 0.002; 14.66 ± 5.18 μmol/L vs 29.72 ± 6.10 μmol/L, P = 0.003; 11.95 ± 2.34 μmol/L vs 29.72 ± 6.10 μmol/L, P = 0.002, respectively). The tissue NO levels in the S. boulardii, MP and S. boulardii + MP groups were similar. The mean serum and tissue TNF-α levels were determined to be 12.97 ± 18.90 pg/mL and 21.75 ± 15.04 pg/mL in the control group, 18.25 ± 15.44 pg/mL and 25.27 ± 11.95 pg/mL in the TNBS group, 20.59 ± 16.15 pg/mL and 24.39 ± 13.06 pg/mL in the S. boulardii group, 9.05 ± 5.13 pg/mL and 24.46 ± 10.85 pg/mL in the MP group, and 13.95 ± 10.17 pg/mL and 24.26 ± 10.37 pg/mL in the S. boulardii + MP group. Significant differences in terms of the levels of serum and tissue TNF-α and the macroscopic and microscopic scores were not found between the groups. S. boulardii fungemia was not observed in any of the rats. However, Candida fungemia was detected in one rat (14%) in the TNBS group, two rats (28%) in the S. boulardii group, three rats (50%) in the MP group, and three rats (42%) in S. boulardii + MP group.
CONCLUSION: S. boulardii does not demonstrate considerable effects on the DAI, pathological scores, or cytokine levels but does decrease the tissue NO levels.

Entities:  

Keywords:  Fungemia; Nitric oxide; Rat; Saccharomyces boulardii; Trinitrobenzene sulfonic acid; Tumor necrosis factor-α

Mesh:

Substances:

Year:  2012        PMID: 23197891      PMCID: PMC3508640          DOI: 10.3748/wjg.v18.i44.6452

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  Herpes simplex virus type 2 synergizes with interferon-gamma in the induction of nitric oxide production in mouse macrophages through autocrine secretion of tumour necrosis factor-alpha.

Authors:  H Baskin; S Ellermann-Eriksen; J Lovmand; S C Mogensen
Journal:  J Gen Virol       Date:  1997-01       Impact factor: 3.891

Review 2.  Effects of Saccharomyces boulardii on intestinal mucosa.

Authors:  Jean-Paul Buts; Nadine De Keyser
Journal:  Dig Dis Sci       Date:  2006-07-13       Impact factor: 3.199

3.  Are probiotics effective in the treatment of fungal colonization of the gastrointestinal tract? Experimental and clinical studies.

Authors:  M Zwolińska-Wcisło; T Brzozowski; T Mach; A Budak; D Trojanowska; P C Konturek; R Pajdo; D Drozdowicz; S Kwiecień
Journal:  J Physiol Pharmacol       Date:  2006-11       Impact factor: 3.011

4.  Effectiveness of bombesin and Saccharomyces boulardii against the translocation of Candida albicans in the digestive tract in immunosuppressed rats.

Authors:  Cem Algin; Adnan Sahin; Nuri Kiraz; Varol Sahintürk; Enver Ihtiyar
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

Review 5.  Probiotic use in clinical practice: what are the risks?

Authors:  Robert J Boyle; Roy M Robins-Browne; Mimi L K Tang
Journal:  Am J Clin Nutr       Date:  2006-06       Impact factor: 7.045

6.  Lactobacillus fermentum, a probiotic capable to release glutathione, prevents colonic inflammation in the TNBS model of rat colitis.

Authors:  Laura Peran; Desiree Camuesco; Monica Comalada; Ana Nieto; Angel Concha; José Luis Adrio; Mónica Olivares; Jordi Xaus; Antonio Zarzuelo; Julio Galvez
Journal:  Int J Colorectal Dis       Date:  2005-07-29       Impact factor: 2.571

7.  Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis.

Authors:  C K Ameho; A A Adjei; E K Harrison; K Takeshita; T Morioka; Y Arakaki; E Ito; I Suzuki; A D Kulkarni; A Kawajiri; S Yamamoto
Journal:  Gut       Date:  1997-10       Impact factor: 23.059

8.  Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects.

Authors:  Benoit Foligné; Sophie Nutten; Lothar Steidler; Véronique Dennin; Denise Goudercourt; Annick Mercenier; Bruno Pot
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

9.  The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis.

Authors:  Sang Kil Lee; Youn Wha Kim; Sung-Gil Chi; Yeong-Shil Joo; Hyo Jong Kim
Journal:  Dig Dis Sci       Date:  2008-07-10       Impact factor: 3.199

10.  Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression.

Authors:  Stavros Sougioultzis; Simos Simeonidis; K Ramakrishnan Bhaskar; Xinhua Chen; Pauline M Anton; Sarah Keates; Charalabos Pothoulakis; Ciarán P Kelly
Journal:  Biochem Biophys Res Commun       Date:  2006-02-23       Impact factor: 3.575

View more
  3 in total

Review 1.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 2.  Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system.

Authors:  Heike Stier; Stephan C Bischoff
Journal:  Clin Exp Gastroenterol       Date:  2016-09-13

3.  Hydrogen peroxide production by lactobacilli promotes epithelial restitution during colitis.

Authors:  Ashish K Singh; Rosanne Y Hertzberger; Ulla G Knaus
Journal:  Redox Biol       Date:  2018-02-12       Impact factor: 11.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.